Vimian Group (VIMIAN) Q2 2024 earnings summary

Executive summary

• Achieved 12% net revenue growth and 11% organic growth in Q2 2024, with strong margin expansion and double-digit growth in Specialty Pharma, MedTech, and Veterinary Services.

• Adjusted EBITA rose 22% year-over-year to EUR 24.7m, with margin improving to 27.2% from 25.0%.

• Net profit for Q2 was EUR 5.1m, up 57% year-over-year; EPS stable at EUR 0.01.

• Leverage reduced to 1.4x following a successful capital raise, positioning for further acquisitions.

• Cash flow from operating activities rebounded to EUR 5.9m in Q2.

Financial highlights

• Q2 revenue: EUR 91.0m (+12% y/y); Q2 adjusted EBITA: EUR 24.7m (27.2% margin, +22% y/y).

• Operating profit (EBIT) was EUR 13.2m, a 30% year-over-year increase.

• Net profit rose 57% to EUR 5.1m compared to EUR 3.2m last year.

• Cash and cash equivalents at EUR 41.2m at end of June.

• Non-recurring items totaled EUR 5.8m, mainly due to U.S. patent litigation legal costs.

Outlook and guidance

• Confident in delivering a solid full year for 2024, supported by strong momentum in Specialty Pharma and Veterinary Services.

• Focus remains on organic and acquisition-driven growth, operational improvements, and talent development.

• Diagnostics expected to maintain current margin profile for the rest of the year, with meaningful revenue impact from new products anticipated in 2025.

• Non-recurring items expected to decrease in H2 as legal processes move to a less intense phase.

• Well-capitalized post-rights issue, with strategic priorities to broaden portfolio and geographic reach.